{"entity":{"id":"granza-bio","kind":"company","name":"Granza Bio","aka":[],"tldr":"Granza Bio is turning the natural attack particles that killer immune cells fire at their targets into programmable medicines that can re-arm exhausted immune cells against cancer.","summary":"Granza Bio builds on the discovery of supramolecular attack particles, the cytotoxic granules that cytotoxic T cells and natural killer cells release to kill targets, and engineers them into programmable therapeutics that deliver localised cell killing and re-arm exhausted immune cells, with applications from cancer to autoimmunity. The company is an Oxford-linked spin-out based in San Francisco and is preclinical; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/granza-bio"},{"label":"Official website","url":"https://www.granzabio.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["cytokine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.granzabio.com","stage":"startup","ycBatch":"W24","investors":["y-combinator"],"funding":[]},"route":"/companies/granza-bio/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"}],"company":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"}]}}